Business Context and Reporting Period
This Form 8-K Current Report was filed by Armata Pharmaceuticals, Inc. (NYSE American: ARMP) on July 18, 2026, covering events occurring on July 17, 2026. The filing primarily addresses executive leadership changes and associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms.
Material Changes
- Executive Promotion: David House was promoted from Senior Vice President, Finance to Chief Financial Officer (CFO), effective July 17, 2026.
- Compensation Structure: Mr. House's new employment agreement establishes an annual base salary of $371,315 and a target annual bonus of 50% of base salary.
- Equity Awards: The company intends to grant Mr. House annual equity awards with a grant date fair value of approximately $300,000, commencing in fiscal year 2026, subject to standard vesting schedules.
- Contract Alignment: The definition of "Change in Control" in the employment agreement of Chief Business Officer Pierre Kyme was amended to align with the new CFO agreement and other senior executive contracts.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of operational risks. It details severance provisions for the CFO, including 12 months of base salary upon termination without "Cause" or resignation for "Good Reason," and full acceleration of time-based equity vesting in the event of an involuntary termination surrounding a "Change in Control."
Investor Verification Checklist
- Verify the full text of the Employment Letter Agreement (Exhibit 10.1) for specific definitions of "Cause" and "Good Reason."
- Review the Amendment to Pierre Kyme's agreement (Exhibit 10.2) to confirm the standardized "Change in Control" definition across the executive team.
- Confirm the vesting schedule details for the intended $300,000 annual equity award, as the filing states these are based on terms granted to other senior executives.
- Check subsequent filings for the actual grant date and terms of the 2026 equity award to Mr. House.